ClinicalTrials.gov
ClinicalTrials.gov Menu

enLighten Laser With MLA Handpiece for Treatment of Moderate and Severe Acne Scars

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03284333
Recruitment Status : Active, not recruiting
First Posted : September 15, 2017
Last Update Posted : March 15, 2018
Sponsor:
Information provided by (Responsible Party):
Cutera Inc.

Brief Summary:
The purpose of this pivotal investigation is to evaluate the efficacy and safety of the Cutera enlighten multi-wavelength 532 nm and 1064 nm Nd:YAG picosecond pulse duration laser and an investigational micro-lens array (MLA) handpiece attachment for improvement of acne scars.

Condition or disease Intervention/treatment Phase
Acne Scars - Mixed Atrophic and Hypertrophic Device: other Not Applicable

Detailed Description:

This is an open-label, prospective, multicenter, pivotal study in up to 45 male or female subjects, age 18 to 65 years who desire laser treatment for the improvement of acne scars. Subjects will receive up to 6 laser treatments, spaced 6 weeks (± 2 weeks) apart with the Cutera enlighten laser with the Micro-Lens Array handpiece attachment. Subjects will be contacted by phone 7 days (± 2 days) after their first treatment for follow-up. Subjects will return to the site after all study treatments have been delivered for two follow-up visits: 6 and 12 weeks (± 2 weeks) following their final study treatment.

  1. The Primary Efficacy Endpoint as the correct identification of the 12 weeks post final treatment photographs from the baseline by at least two of the three blinded reviewers in 75% of the patients and an improvement of one point in the ASAS.
  2. The Secondary Efficacy Endpoints as the:

    • Efficacy of the Cutera enlighten laser with the Micro-Lens Array handpiece attachment treatment as assessed by the investigator starting from the 2nd treatment onward, and
    • Subject satisfaction levels as assessed from the subject questionnaire completed at the final follow-up visit 12 weeks post final treatment.
  3. The Safety Endpoint as the safety of the Cutera enlighten laser with Micro-Lens Array handpiece attachment as assessed by the frequency and severity of device related adverse events,
  4. The Exploratory Analysis as the Efficacy of the Cutera enlighten laser with a Micro-Lens Array handpiece attachment for the improvement of skin quality as assessed by the investigator and/or blinded evaluators 12-weeks-post final study treatment.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 42 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Open-label, Prospective, Multicenter Study to Evaluate the Cutera enLighten™ Laser and a Micro-Lens Array Handpiece Attachment for the Treatment of Moderate and Severe Acne Scars
Actual Study Start Date : July 27, 2017
Estimated Primary Completion Date : September 2018
Estimated Study Completion Date : September 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Acne Scars

Arm Intervention/treatment
Experimental: other
no arm
Device: other
no arm




Primary Outcome Measures :
  1. Correct identification of the 12 weeks Post-final treatment photographs from the Baseline photographs by at least 2 of the 3 blinded reviewers in 75% of the patients. [ Time Frame: 12 weeks post-final treatment ]
    visual review of study photographs correctly identifying the temporal order (before and after) of each photograph pair (Baseline and 12 week Post-final treatment)

  2. Improvement of at least 1 point in the ASAS as assessed by Investigator. [ Time Frame: 12 weeks post-final treatment ]
    ASAS= Acne Scar Assessment Scale [1(clear), 2(Very Mild), 3(Mild), 4(Moderate) to 5(Severe)]


Secondary Outcome Measures :
  1. 1. Efficacy of Cutera enLighten device with MLA handpiece attachment as assessed by Investigator (GAIS). [ Time Frame: 12 weeks post-screening through study completion, an average of 1 year. ]
    GAIS =+3=Significant Improvement, +2=Moderate Improvement, +1=Mild Improvement and 0=No Change.

  2. 2. Satisfaction level and assessment of Acne Scar improvement as assessed by Subject. [ Time Frame: 12 weeks post-final treatment ]
    Satisfaction level and assessment of Acne Scar improvement

  3. 3. Efficacy of Cutera enLighten device with MLA handpiece attachment as assessed by Investigator (ASAS). [ Time Frame: 12 weeks post-screening through study completion, an average of 1 year. ]
    ASAS= Acne Scar Assessment Scale [1(clear), 2(Very Mild), 3(Mild), 4(Moderate) to 5(Severe)]

  4. 4. Efficacy of Cutera enLighten device with MLA handpiece attachment as assessed by Investigator for Radiance, Smoothness, Pigmentation, Erythema and Pore size (Skin Quality Rating.) [ Time Frame: 12 weeks post-screening through study completion, an average of 1 year. ]
    Skin Quality Rating = scale: 1(No radiance) - 10(maximum radiance), 1(Very rough) - 10(Very smooth), 1=(Very irregular pigmentation) - 10(Very uniform pigmentation), 1=(Intense redness) - 10(No redness), 1=(Very large pores) - 10=Minimal pores)


Other Outcome Measures:
  1. Frequency and severity of device related Adverse Events of Cutera enLighten device with MLA handpiece attachment [ Time Frame: through study completion, an average of 1 year. ]
    Incidence of Treatment-emergent Adverse Events



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Subject must be able to read, understand and sign the Informed Consent Form.
  2. Female or Male, 18 to 65 years of age (inclusive).
  3. Fitzpatrick Skin Type I - VI (Appendix 6).
  4. Subject desires treatment for acne scars and wishes to undergo laser treatments for improvement.
  5. Subject has bilateral moderate to severe signs of facial acne scarring.
  6. Must be willing to have Cutera enlighten laser with the Micro-Lens Array handpiece attachment treatments and able to adhere to the treatments, follow-up visit schedule, and post-treatment care instructions.
  7. Willing to have very limited sun exposure and use sunscreen on the treatment area every day for the duration of the study, including the follow-up period.
  8. Willing to have digital photographs taken of the treatment area and agree to use of photographs for presentation (educational and/or marketing), publications, and any additional marketing purposes.
  9. Agree to not undergo any other procedure(s) or treatment(s) for acne scars during the study and has no intention of having such procedures performed during the course of the study.
  10. For female subjects: not pregnant or lactating and is either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study.,

    Exclusion Criteria:

1. Participation in a clinical trial of another drug, or device administered to the treatment area, within 6 months prior to enrollment or during the study.

2. Any type of prior cosmetic treatment to the target area within 6 months of study participation, such as laser procedures, facial fillers, i.e. (Bellafill) and those used for general aesthetic correction, facial peel, lightening creams, or facial surgery.

3. Use of prescription topicals in the treatment area within one month prior to treatment or use of topical agents one week prior to treatment that may cause facial sensitivity.

4. Suffering from significant skin conditions in the treated areas or inflammatory skin conditions, including but not limited to, open lacerations or abrasions, hidradenitis, rash, infection , or dermatitis of the treatment area prior to treatment (duration of resolution as per the Investigator's discretion).

5. Pregnant and/or breastfeeding, or planning to become pregnant. 6. Significant concurrent illness, such as diabetes mellitus, immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or using immunosuppressive medication.

7. Hypersensitivity to light exposure. 8. Any use of medication that is known to increase sensitivity to light according to the Investigator's discretion.

9. History of keloid scarring, hypertrophic scarring or abnormal wound healing or prone to bruising.

10. Has a history of squamous cell carcinoma or melanoma in the treatment area. 11. History of epidermal or dermal disorders (particularly if involving collagen or microvascularity), including collagen vascular disease or vasculitic disorders.

12. A history or active skin condition that in the opinion of the Investigator may interfere/confound with the treatment.

13. History of connective tissue disease, such as systemic lupus erythematosus or scleroderma.

14. History of disease stimulated by heat, such as recurrent herpes simplex and/or herpes zoster (shingles) in the treatment area, unless treatment is conducted following a prophylactic regimen.

15. History of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation, or any that are considered not acceptable by the study investigator.

16. Has used oral isotretinoin (Accutane or therapeutic vitamin A supplements of ≥ 10,000 units per day) within 12 months of initial treatment or plans on using during the course of the study (note: skin must regain its normal degree of moisture prior to treatment, e.g. lack of noticeable skin flaking and peeling).

17. Excessively tanned or active sun tan in facial area to be treated, or unable/unlikely to refrain from tanning during the study.

19. Excessive facial hair in the area to be treated (beards, sideburns, and/or moustache,) that would interfere with diagnosis, assessment, and treatment.

20. As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study, including excessive alcohol or drug abuses, or a condition that would compromise the subject's ability to comply with the study requirements.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03284333


Locations
United States, California
Cutera Research Center
Brisbane, California, United States, 94005
United States, New York
Sadick Dermatology/Sadick Research Center
New York, New York, United States, 10075
Sponsors and Collaborators
Cutera Inc.
Investigators
Principal Investigator: Stephen Ronan, M.D. Cutera Research Center
Principal Investigator: Neil Sadick, M.D. Sadick Dermatology/Sadick Research Center

Responsible Party: Cutera Inc.
ClinicalTrials.gov Identifier: NCT03284333     History of Changes
Other Study ID Numbers: C-17-ML02
First Posted: September 15, 2017    Key Record Dates
Last Update Posted: March 15, 2018
Last Verified: September 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Product Manufactured in and Exported from the U.S.: Yes

Additional relevant MeSH terms:
Hypertrophy
Pathological Conditions, Anatomical